BiomX's Phage Therapy Shows Promising Results for Antibiotic-Resistant Infections

BiomX's phage therapy platform has been validated through a first-in-human Phase 1b/2a trial for antibiotic-resistant P. aeruginosa infections. The trial demonstrated a 2.7 log₁₀ (500-fold) bacteria reduction compared to placebo, with no emergent resistance and preservation of a healthy microbiome. BiomX is advancing its Phase 2b trial of BX004 with topline results expected Q1 2026.